Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089534556> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2089534556 endingPage "45" @default.
- W2089534556 startingPage "40" @default.
- W2089534556 abstract "The safety and tolerability of repetitive doses of the boneseeking radiopharmaceutical samarium-153 lexidronam (153Sm- EDTMP) were investigated in men with hormone-naive prostate cancer metastatic to bone.Within 30 days of initiating androgen deprivation, the first of 4 planned doses of 153Sm- EDTMP given every 12 weeks was administered. Growth factors were not permitted. The first cohort of 6 patients received 153Sm-EDTMP at 2 mCi/kg per dose; 3 patients completed all 4 doses and 3 received 3 doses.There were 7 episodes of grade 3 neutropenia and 1 each of grade 3 and 4 thrombocytopenia. Of 6 patients in the second cohort who received 153Sm-EDTMP 2.5 mCi/kg per dose, only 1 received all 4 doses. Four events of grade 3 neutropenia and 2 events of grade 3 thrombocytopenia were reported. The 12-week dose schedule resulted in persistent low-grade thrombocytopenia and/or leukopenia, which prevented administration of all 4 planned doses. As a result, the dose of 153Sm-EDTMP was decreased to 2 mCi/kg for a total of 3 doses administered every 16 weeks. Five of 6 patients in this cohort received all 3 doses of 153Sm-EDTMP. There were 7 episodes of reversible grade 3 neutropenia. For all 18 patients on the study, there were no drug-related serious adverse events or grade 4 nonhemmatologic toxicities.In men with hormone-naive prostate cancer metastatic to bone, the feasible dose and schedule for repeated doses of 153Sm-EDTMP is 2 mCi/kg given every 16 weeks for 3 doses." @default.
- W2089534556 created "2016-06-24" @default.
- W2089534556 creator A5001591556 @default.
- W2089534556 creator A5027597209 @default.
- W2089534556 creator A5073246821 @default.
- W2089534556 creator A5089081817 @default.
- W2089534556 date "2008-03-01" @default.
- W2089534556 modified "2023-09-26" @default.
- W2089534556 title "Safety Analysis of Repeated High Doses of Samarium-153 Lexidronam in Men with Hormone-Naive Prostate Cancer Metastatic to Bone" @default.
- W2089534556 cites W1935714962 @default.
- W2089534556 cites W1985630081 @default.
- W2089534556 cites W1986170691 @default.
- W2089534556 cites W2007745674 @default.
- W2089534556 cites W2008386697 @default.
- W2089534556 cites W2043103956 @default.
- W2089534556 cites W2063458830 @default.
- W2089534556 cites W2081463541 @default.
- W2089534556 cites W2127479326 @default.
- W2089534556 cites W2158639339 @default.
- W2089534556 doi "https://doi.org/10.3816/cgc.2008.n.007" @default.
- W2089534556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18501082" @default.
- W2089534556 hasPublicationYear "2008" @default.
- W2089534556 type Work @default.
- W2089534556 sameAs 2089534556 @default.
- W2089534556 citedByCount "12" @default.
- W2089534556 countsByYear W20895345562013 @default.
- W2089534556 countsByYear W20895345562014 @default.
- W2089534556 countsByYear W20895345562015 @default.
- W2089534556 countsByYear W20895345562017 @default.
- W2089534556 countsByYear W20895345562020 @default.
- W2089534556 countsByYear W20895345562022 @default.
- W2089534556 crossrefType "journal-article" @default.
- W2089534556 hasAuthorship W2089534556A5001591556 @default.
- W2089534556 hasAuthorship W2089534556A5027597209 @default.
- W2089534556 hasAuthorship W2089534556A5073246821 @default.
- W2089534556 hasAuthorship W2089534556A5089081817 @default.
- W2089534556 hasConcept C121608353 @default.
- W2089534556 hasConcept C126322002 @default.
- W2089534556 hasConcept C126894567 @default.
- W2089534556 hasConcept C197934379 @default.
- W2089534556 hasConcept C2777063308 @default.
- W2089534556 hasConcept C2778375690 @default.
- W2089534556 hasConcept C2780192828 @default.
- W2089534556 hasConcept C2780873365 @default.
- W2089534556 hasConcept C29730261 @default.
- W2089534556 hasConcept C71924100 @default.
- W2089534556 hasConcept C72563966 @default.
- W2089534556 hasConceptScore W2089534556C121608353 @default.
- W2089534556 hasConceptScore W2089534556C126322002 @default.
- W2089534556 hasConceptScore W2089534556C126894567 @default.
- W2089534556 hasConceptScore W2089534556C197934379 @default.
- W2089534556 hasConceptScore W2089534556C2777063308 @default.
- W2089534556 hasConceptScore W2089534556C2778375690 @default.
- W2089534556 hasConceptScore W2089534556C2780192828 @default.
- W2089534556 hasConceptScore W2089534556C2780873365 @default.
- W2089534556 hasConceptScore W2089534556C29730261 @default.
- W2089534556 hasConceptScore W2089534556C71924100 @default.
- W2089534556 hasConceptScore W2089534556C72563966 @default.
- W2089534556 hasIssue "1" @default.
- W2089534556 hasLocation W20895345561 @default.
- W2089534556 hasLocation W20895345562 @default.
- W2089534556 hasOpenAccess W2089534556 @default.
- W2089534556 hasPrimaryLocation W20895345561 @default.
- W2089534556 hasRelatedWork W1833952634 @default.
- W2089534556 hasRelatedWork W2056387366 @default.
- W2089534556 hasRelatedWork W2061438827 @default.
- W2089534556 hasRelatedWork W2075571760 @default.
- W2089534556 hasRelatedWork W2162645459 @default.
- W2089534556 hasRelatedWork W2524109715 @default.
- W2089534556 hasRelatedWork W3002913219 @default.
- W2089534556 hasRelatedWork W3046627754 @default.
- W2089534556 hasRelatedWork W3154567952 @default.
- W2089534556 hasRelatedWork W4214889510 @default.
- W2089534556 hasVolume "6" @default.
- W2089534556 isParatext "false" @default.
- W2089534556 isRetracted "false" @default.
- W2089534556 magId "2089534556" @default.
- W2089534556 workType "article" @default.